Current concepts and future directions in radioimmunotherapy.

Area of Science:

• Oncology
• Immunology
• Nuclear Medicine

Background:

• Immunotherapy for cancer has limitations in intrinsic tumor cell killing and penetration into poorly vascularized tumors.
• Radioimmunotherapy (RIT) was developed to overcome these limitations by conjugating antibodies with radioisotopes.

Purpose of the Study:

• To review the principles, current applications, and challenges of radioimmunotherapy in cancer treatment.
• To discuss the potential of RIT in lymphoma and other cancers, and future optimization strategies.

Main Methods:

• Review of existing literature on radioimmunotherapy, focusing on FDA-approved agents and ongoing research.
• Analysis of the mechanisms of action, clinical applications, and barriers to RIT adoption.

Main Results:

• Anti-CD20 monoclonal antibodies, such as Ibritumomab Tiuxetan (Zevalin®) and Tositumomab (Bexxar®), are FDA-approved RIT agents for lymphomas.
• Despite over 8 years post-approval, RIT faces medical, scientific, logistical, and financial barriers to widespread use.
• Research is exploring earlier use in lymphoma treatment, other cancers, and novel approaches like pre-targeting and alpha/Auger emitters.

Conclusions:

• Radioimmunotherapy offers enhanced cytotoxic effects and improved tumor penetration compared to conventional immunotherapy.
• Overcoming existing barriers is crucial for broader clinical implementation and realizing the full potential of RIT.
• Future research directions include optimizing delivery, exploring new radioisotopes, and expanding applications to solid tumors and infections.